(UBS) UBS - Ratings and Ratios

Exchange: NYSE • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: CH0244767585

Wealth Management, Banking, Asset Management, Investment Bank

UBS EPS (Earnings per Share)

EPS (Earnings per Share) of UBS over the last years for every Quarter: "2020-09": 0.56, "2020-12": 0.46, "2021-03": 0.49, "2021-06": 0.55, "2021-09": 0.63, "2021-12": 0.38, "2022-03": 0.61, "2022-06": 0.61, "2022-09": 0.52, "2022-12": 0.5, "2023-03": 0.32, "2023-06": -0.02, "2023-09": -0.24, "2023-12": -0.51, "2024-03": 0.52, "2024-06": 0.34, "2024-09": 0.53, "2024-12": 0.39, "2025-03": 0.6, "2025-06": 0.82, "2025-09": 0,

UBS Revenue

Revenue of UBS over the last years for every Quarter: 2020-09: 8181, 2020-12: 8183, 2021-03: 8675, 2021-06: 8895, 2021-09: 9015, 2021-12: 8716, 2022-03: 9382, 2022-06: 8067, 2022-09: 7956, 2022-12: 7988, 2023-03: 8698, 2023-06: 9509, 2023-09: 10644, 2023-12: 10417, 2024-03: 11941, 2024-06: 11853, 2024-09: 10960, 2024-12: 10556, 2025-03: 10935.197, 2025-06: 18582, 2025-09: null,

Description: UBS UBS September 25, 2025

UBS Group AG (NYSE:UBS) is a Swiss-based, globally diversified financial services firm that delivers advice and solutions to private, institutional, and corporate clients across five operating divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, Investment Bank, and Non-core & Legacy.

Its product suite spans traditional banking (deposits, credit/debit cards, mortgage and structured lending) and wealth-management services (estate planning, retirement solutions, multi-asset investment strategies), as well as corporate and institutional offerings such as equity & debt capital markets, syndicated credit, transaction banking, trade finance, and global custody.

On the investment-side, UBS provides access to equities, fixed income, hedge funds, real-estate and private-market assets, alongside indexed and alternative beta strategies, customized multi-asset solutions, and fiduciary advisory services. It also facilitates securities trading, risk-management, and liquidity provision across FX, rates, credit, and precious-metal markets.

Key quantitative indicators (as of FY 2023) include CHF 30 billion in assets under management, a net profit of CHF 7.5 billion, and a cost-to-income ratio of roughly 68 %, reflecting ongoing efficiency drives in a low-interest-rate environment. The firm’s return on equity (ROE) hovered around 12 %, consistent with peers in the diversified capital-markets sector.

Macro-level drivers that materially affect UBS’s outlook are: (1) the trajectory of global interest rates, which influence net interest margins in banking; (2) wealth-creation trends in Asia-Pacific, underpinning growth in Global Wealth Management; and (3) regulatory capital requirements that shape the scale and profitability of its investment-banking activities.

For a deeper quantitative comparison of UBSs valuation metrics against peers, the ValueRay platform offers a granular, data-driven dashboard worth exploring.

UBS Stock Overview

Market Cap in USD 123,883m
Sub-Industry Diversified Capital Markets
IPO / Inception 2014-11-21

UBS Stock Ratings

Growth Rating 90.2%
Fundamental 57.0%
Dividend Rating 36.3%
Return 12m vs S&P 500 5.73%
Analyst Rating 2.50 of 5

UBS Dividends

Dividend Yield 12m 3.46%
Yield on Cost 5y 13.99%
Annual Growth 5y -7.93%
Payout Consistency 68.7%
Payout Ratio 57.9%

UBS Growth Ratios

Growth Correlation 3m 15.4%
Growth Correlation 12m 78.1%
Growth Correlation 5y 95.9%
CAGR 5y 40.42%
CAGR/Max DD 3y (Calmar Ratio) 1.50
CAGR/Mean DD 3y (Pain Ratio) 8.12
Sharpe Ratio 12m 1.23
Alpha 7.90
Beta 0.916
Volatility 26.25%
Current Volume 1947.5k
Average Volume 20d 1827k
Stop Loss 37.9 (-3%)
Signal -0.01

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (6.28b TTM) > 0 and > 6% of Revenue (6% = 3.06b TTM)
FCFTA 0.11 (>2.0%) and ΔFCFTA 5.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -994.5% (prev -1189 %; Δ 194.6pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.11 (>3.0%) and CFO 185.93b > Net Income 6.28b (YES >=105%, WARN >=100%)
Net Debt (204.02b) to EBITDA (17.73b) ratio: 11.50 <= 3.0 (WARN <= 3.5)
Current Ratio 0.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (3.31b) change vs 12m ago -1.57% (target <= -2.0% for YES)
Gross Margin 37.42% (prev 98.78%; Δ -61.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 3.16% (prev 2.87%; Δ 0.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.46 (EBITDA TTM 17.73b / Interest Expense TTM 30.67b) >= 6 (WARN >= 3)

Altman Z'' -1.72

(A) -0.30 = (Total Current Assets 410.45b - Total Current Liabilities 917.96b) / Total Assets 1669.99b
(B) 0.05 = Retained Earnings (Balance) 79.73b / Total Assets 1669.99b
(C) 0.01 = EBIT TTM 14.12b / Avg Total Assets 1615.48b
(D) 0.05 = Book Value of Equity 85.55b / Total Liabilities 1580.29b
Total Rating: -1.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.97

1. Piotroski 3.50pt = -1.50
2. FCF Yield 127.3% = 5.0
3. FCF Margin data missing
4. Debt/Equity 2.87 = -0.58
5. Debt/Ebitda 11.50 = -2.50
6. ROIC - WACC (= -1.36)% = -1.70
7. RoE 7.21% = 0.60
8. Rev. Trend 82.23% = 6.17
9. EPS Trend 29.73% = 1.49

What is the price of UBS shares?

As of October 29, 2025, the stock is trading at USD 39.09 with a total of 1,947,482 shares traded.
Over the past week, the price has changed by +4.07%, over one month by -5.42%, over three months by +3.47% and over the past year by +26.59%.

Is UBS a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, UBS is currently (October 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 56.97 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UBS is around 50.01 USD . This means that UBS is currently undervalued and has a potential upside of +27.94% (Margin of Safety).

Is UBS a buy, sell or hold?

UBS has received a consensus analysts rating of 2.50. Therefor, it is recommend to sell UBS.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 1
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the UBS price?

Issuer Target Up/Down from current
Wallstreet Target Price 41.2 5.3%
Analysts Target Price 41.2 5.3%
ValueRay Target Price 54 38.2%

UBS Fundamental Data Overview October 29, 2025

Market Cap USD = 123.88b (123.88b USD * 1.0 USD.USD)
P/E Trailing = 20.3594
P/E Forward = 14.3678
P/S = 2.6352
P/B = 1.432
P/EG = 0.5909
Beta = 0.916
Revenue TTM = 51.03b USD
EBIT TTM = 14.12b USD
EBITDA TTM = 17.73b USD
Long Term Debt = 307.98b USD (from longTermDebt, last quarter)
Short Term Debt = 31.93b USD (from shortTermDebt, last quarter)
Debt = 256.64b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 204.02b USD (from netDebt column, last quarter)
Enterprise Value = 144.33b USD (123.88b + Debt 256.64b - CCE 236.19b)
Interest Coverage Ratio = 0.46 (Ebit TTM 14.12b / Interest Expense TTM 30.67b)
FCF Yield = 127.3% (FCF TTM 183.72b / Enterprise Value 144.33b)
FCF Margin = 360.0% (FCF TTM 183.72b / Revenue TTM 51.03b)
Net Margin = 12.31% (Net Income TTM 6.28b / Revenue TTM 51.03b)
Gross Margin = 37.42% ((Revenue TTM 51.03b - Cost of Revenue TTM 31.94b) / Revenue TTM)
Gross Margin QoQ = 58.92% (prev 35.55%)
Tobins Q-Ratio = 0.09 (Enterprise Value 144.33b / Total Assets 1669.99b)
Interest Expense / Debt = 2.66% (Interest Expense 6.82b / Debt 256.64b)
Taxrate = -9.53% (negative due to tax credits) (-209.0m / 2.19b)
NOPAT = 15.46b (EBIT 14.12b * (1 - -9.53%)) [negative tax rate / tax credits]
Current Ratio = 0.45 (Total Current Assets 410.45b / Total Current Liabilities 917.96b)
Debt / Equity = 2.87 (Debt 256.64b / totalStockholderEquity, last quarter 89.28b)
Debt / EBITDA = 11.50 (Net Debt 204.02b / EBITDA 17.73b)
Debt / FCF = 1.11 (Net Debt 204.02b / FCF TTM 183.72b)
Total Stockholder Equity = 87.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.38% (Net Income 6.28b / Total Assets 1669.99b)
RoE = 7.21% (Net Income TTM 6.28b / Total Stockholder Equity 87.14b)
RoCE = 3.57% (EBIT 14.12b / Capital Employed (Equity 87.14b + L.T.Debt 307.98b))
RoIC = 3.66% (NOPAT 15.46b / Invested Capital 422.76b)
WACC = 5.02% (E(123.88b)/V(380.52b) * Re(9.39%) + D(256.64b)/V(380.52b) * Rd(2.66%) * (1-Tc(-0.10)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.25%
[DCF Debug] Terminal Value 68.57% ; FCFE base≈141.63b ; Y1≈109.86b ; Y5≈70.13b
Fair Price DCF = 332.1 (DCF Value 1052.52b / Shares Outstanding 3.17b; 5y FCF grow -26.71% → 3.0% )
EPS Correlation: 29.73 | EPS CAGR: -20.84% | SUE: -1.14 | # QB: 0
Revenue Correlation: 82.23 | Revenue CAGR: 36.13% | SUE: 0.67 | # QB: 0

Additional Sources for UBS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle